Blue Owl Capital Holdings LP recently acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), investing approximately $1.52 million during the third quarter of 2023. According to HoldingsChannel.com, the institutional investor purchased 125,000 shares of the specialty pharmaceutical company’s stock, marking a significant addition to its portfolio.
Other institutional investors also adjusted their holdings in KalVista Pharmaceuticals. The Manufacturers Life Insurance Company increased its stake by 5.9% in the second quarter, bringing its total to 14,626 shares valued at around $165,000 after acquiring an additional 818 shares. Similarly, BNP Paribas Financial Markets raised its holdings by 47.0%, now owning 4,041 shares worth approximately $46,000 following a purchase of 1,292 shares.
In addition, Rhumbline Advisers increased its position by 2.8%, resulting in ownership of 54,376 shares valued at about $615,000. The Police & Firemen’s Retirement System of New Jersey lifted its stake by 26.8%, now holding 9,756 shares valued at approximately $110,000 after acquiring an additional 2,061 shares. Lastly, Profund Advisors LLC boosted its holdings by 25.9%, increasing its total to 12,613 shares worth around $154,000.
Insider Transactions and Market Activity
Recent insider transactions have also drawn attention. Brian Piekos, the Chief Financial Officer, sold 1,767 shares on February 23, 2024, at an average price of $15.57, resulting in a total value of $27,512.19. Following this sale, Piekos holds 13,762 shares valued at approximately $214,274.34, reflecting an 11.38% decrease in his position.
Another insider, Paul K. Audhya, sold 5,354 shares on the same date for a total transaction amount of $83,361.78. This sale reduced Audhya’s ownership to 138,983 shares, valued at around $2,163,965.31, a decrease of 3.71% from his previous position. Over the last three months, insiders have sold a total of 33,979 shares worth $535,091. Currently, insiders own 4.30% of KalVista’s stock.
Stock Performance and Company Overview
On February 23, 2024, KalVista Pharmaceuticals’ stock opened at $16.23. The company’s 50-day simple moving average stands at $15.57, while the 200-day moving average is $14.11. KalVista has a market capitalization of approximately $820.43 million and has reported a price-to-earnings (P/E) ratio of -4.11. The company’s debt-to-equity ratio is notably high at 8.18, with a quick ratio of 7.21 and a current ratio of 7.22. Over the past year, the stock has fluctuated between a low of $9.23 and a high of $19.00.
KalVista Pharmaceuticals is a clinical-stage biotechnology firm dedicated to the discovery and development of small-molecule protease inhibitors for rare and specialty diseases. The company’s scientific efforts focus on selectively inhibiting plasma kallikrein, a serine protease associated with conditions characterized by vascular leak, edema, and inflammation. Its lead programs include an oral plasma kallikrein inhibitor currently in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks, as well as an intravitreal kallikrein inhibitor aimed at diabetic macular edema.
For further insights on KalVista Pharmaceuticals and its market activities, stakeholders can visit HoldingsChannel.com to access the latest 13F filings and insider trading information.
